Literature DB >> 21904489

Nasal Crohn's disease /apheresis.

David A Schwartz1.   

Abstract

Entities:  

Year:  2008        PMID： 21904489      PMCID： PMC3088839     

Source DB:  PubMed          Journal:  Gastroenterol Hepatol (N Y)        ISSN： 1554-7914


× No keyword cloud information.
  19 in total

1.  Improvement of arthritis and arthralgia after treatment with infliximab (Remicade) in a German prospective, open-label, multicenter trial in refractory Crohn's disease.

Authors:  Hans Herfarth; Florian Obermeier; Tilo Andus; Gerhard Rogler; Susanna Nikolaus; Tanja Kuehbacher; Stefan Schreiber
Journal:  Am J Gastroenterol       Date:  2002-10       Impact factor: 10.864

2.  The prevalence of extraintestinal diseases in inflammatory bowel disease: a population-based study.

Authors:  C N Bernstein; J F Blanchard; P Rawsthorne; N Yu
Journal:  Am J Gastroenterol       Date:  2001-04       Impact factor: 10.864

3.  Infliximab for the treatment of pyoderma gangrenosum: a randomised, double blind, placebo controlled trial.

Authors:  T N Brooklyn; M G S Dunnill; A Shetty; J J Bowden; J D L Williams; C E M Griffiths; A Forbes; R Greenwood; C S Probert
Journal:  Gut       Date:  2005-09-27       Impact factor: 23.059

4.  Pilot feasibility studies of leukocytapheresis with the Adacolumn Apheresis System in patients with active ulcerative colitis or Crohn disease.

Authors:  Bruce E Sands; William J Sandborn; Douglas C Wolf; Seymour Katz; Michael Safdi; David A Schwartz; Stephen B Hanauer
Journal:  J Clin Gastroenterol       Date:  2006-07       Impact factor: 3.062

Review 5.  Treatment trials in ankylosing spondylitis: current and future considerations.

Authors:  D van der Heijde; J Braun; D McGonagle; J Siegel
Journal:  Ann Rheum Dis       Date:  2002-12       Impact factor: 19.103

6.  Treatment of active ankylosing spondylitis with infliximab: a randomised controlled multicentre trial.

Authors:  J Braun; J Brandt; J Listing; A Zink; R Alten; W Golder; E Gromnica-Ihle; H Kellner; A Krause; M Schneider; H Sörensen; H Zeidler; W Thriene; J Sieper
Journal:  Lancet       Date:  2002-04-06       Impact factor: 79.321

7.  Granulocyteaphaeresis in steroid-dependent inflammatory bowel disease: a prospective, open, pilot study.

Authors:  E Domènech; J Hinojosa; M Esteve-Comas; F Gomollón; J M Herrera; G Bastida; A Obrador; R Ruiz; C Saro; M A Gassull
Journal:  Aliment Pharmacol Ther       Date:  2004-12       Impact factor: 8.171

8.  Granulocyte, monocyte/macrophage apheresis for inflammatory bowel disease: the first 100 patients treated in Scandinavia.

Authors:  Tryggve Ljung; Ole Østergaard Thomsen; Morten Vatn; Per Karlén; Lars Norman Karlsen; Curt Tysk; Stefan U Nilsson; Anders Kilander; Rolf Gillberg; Olof Grip; Stefan Lindgren; Ragnar Befrits; Robert Löfberg
Journal:  Scand J Gastroenterol       Date:  2007-02       Impact factor: 2.423

9.  Adsorptive granulocyte and monocyte apheresis for refractory Crohn's disease: an open multicenter prospective study.

Authors:  Yoshihiro Fukuda; Toshiyuki Matsui; Yasuo Suzuki; Kazunari Kanke; Takayuki Matsumoto; Masakazu Takazoe; Takayuki Matsumoto; Satoshi Motoya; Terasu Honma; Koji Sawada; Tsuneyoshi Yao; Takashi Shimoyama; Toshifumi Hibi
Journal:  J Gastroenterol       Date:  2004-12       Impact factor: 7.527

10.  Selective granulocyte and monocyte adsorptive apheresis as a first-line treatment for steroid naïve patients with active ulcerative colitis: a prospective uncontrolled study.

Authors:  Yasuo Suzuki; Naoki Yoshimura; Abby R Saniabadi; Yasushi Saito
Journal:  Dig Dis Sci       Date:  2004-04       Impact factor: 3.199
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.